RankingsPricing
  1. US-listed companies
  2. Protagonist Therapeutics, Inc
  3. Financials
  4. Cash from operations

Protagonist Therapeutics, IncPTGX

Market cap
$5.4B
P/E ratio
SummaryFinancials
Period EndCash from operations (Million USD)YoY (%)
Dec 31, 2024184-362.19%
Dec 31, 2023-70-35.05%
Dec 31, 2022-108+0.25%
Dec 31, 2021-108+48.81%
Dec 31, 2020-72+74.55%
Dec 31, 2019-42-16.86%
Dec 31, 2018-50-1389.95%
Dec 31, 20174-112.92%
Dec 31, 2016-30

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)